Zucara Therapeutics, a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that its positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.
Zucara is an OBIO® member and presented at the OBIO® Investment Summit.